GW Pharmaceuticals (Jazz Pharmaceuticals)

Cambridge, United KingdomFounded 1998

Medical & Pharma NASDAQ: JAZZ gw-pharma.com

Share:X / Twitter LinkedIn Suggest a correction

About GW Pharmaceuticals (Jazz Pharmaceuticals)

GW Pharmaceuticals, now part of Jazz Pharmaceuticals, is the world's leading cannabinoid pharmaceutical company and creator of Epidiolex, the first FDA-approved plant-derived cannabinoid medicine. Based in Cambridge, UK, GW pioneered the development of prescription cannabinoid medicines through rigorous clinical trials. The company's Epidiolex is approved for treating severe forms of epilepsy including Dravet and Lennox-Gastaut syndromes.

Key Facts

1Created Epidiolex, the first FDA-approved plant-derived cannabinoid medicine
2Acquired by Jazz Pharmaceuticals for USD 7.2 billion in 2021
3Epidiolex generates over USD 700 million in annual revenue
4Sativex is approved in over 25 countries for multiple sclerosis spasticity

Latest News

Jazz Pharma's Epidiolex Revenue Jumps 15% on Expanded Cannabis Therapy

8d ago

CBD-based epilepsy drug drives growth as pharmaceutical cannabis applications gain medical acceptance and market traction.

Jazz Pharma Target Slashed as Major Bank Cuts Cannabis Exposure Outlook

16d ago

Leading investment bank dramatically reduces JAZZ price target amid concerns over cannabis pharmaceutical pipeline and market headwinds.

Morgan Stanley Boosts Jazz Pharma Target on Cannabis Drug Strength

17d ago

Wall Street firm increases price target as pharmaceutical giant's cannabis-derived treatments drive revenue growth and market expansion prospects.

View all JAZZ news

Frequently Asked Questions

What is Epidiolex used for?

Epidiolex is a purified cannabidiol (CBD) oral solution approved by the FDA and EMA for treating seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients one year of age and older.

Is GW Pharmaceuticals still an independent company?

No, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals in 2021 for approximately USD 7.2 billion. Its cannabinoid medicines, including Epidiolex and Sativex, are now part of Jazz's neuroscience portfolio.

More Cannabis Companies in Cambridge

Revolutionary Clinics

Retail & Coffeeshop

Margent Farm Cambridgeshire

Producer & Grower

JAZZ Stock

View live price, chart & analysis

Cannabis Laws

Cannabis in United Kingdom

Products

Epidiolex (cannabidiol oral solution)
Sativex (nabiximols oromucosal spray)
Pipeline cannabinoid medicines

Specialties

FDA and EMA-approved cannabinoid medicinesClinical trial-proven cannabis pharmaceuticalsCannabinoid drug discovery and developmentEpilepsy and neurological disorder treatment